TABLE 1.
Group mean relative difference and standard deviation of VT, BPP, and occupancy estimated with the proposed AC methods with respect to AC CT for every ROI.
| Mean RD (%) | Temporal | ACC | Amygdala | Caudate | Putamen | Thalamus | Cerebellum |
| AC DIXON | |||||||
| VT placebo | −11.0 ± 1.7 | −9.7 ± 2.3 | −6.4 ± 1.4 | −7.8 ± 1.4 | −8.2 ± 1.4 | −8.4 ± 1.6 | −11.7 ± 2.6 |
| VT SSRI | −11.1 ± 1.6 | −9.2 ± 1.6 | −6.1 ± 1.7 | −7.0 ± 1.6 | −7.6 ± 1.5 | −7.7 ± 1.5 | −11.8 ± 2.7 |
| BPP placebo | −8.8 ± 4.4 | −4.1 ± 7.9 | −1.5 ± 3.0 | −5.0 ± 1.9 | −5.9 ± 1.8 | −6.6 ± 1.9 | − |
| BPP SSRI | −6.9 ± 11.2 | 7.2 ± 21.2 | 8.8 ± 9.9 | 1.7 ± 4.8 | −1.2 ± 3.4 | −1.5 ± 4.2 | − |
| Occupancy | −2.1 ± 9.3 | −8.7 ± 16.0 | −4.7 ± 2.7 | −3.5 ± 2.5 | −2.8 ± 2.3 | −2.4 ± 2.0 | − |
| AC UTE | |||||||
| VT placebo | −6.5 ± 1.7 | −7.1 ± 1.2 | −4.1 ± 1.9 | −3.9 ± 1.4 | −4.2 ± 1.4 | −3.5 ± 1.4 | −9.0 ± 2.8 |
| VT SSRI | −6.5 ± 2.0 | −7.1 ± 1.0 | −4.3 ± 2.2 | −4.2 ± 1.5 | −4.4 ± 1.4 | −3.5 ± 1.6 | −9.0 ± 2.9 |
| BPP placebo | 0.8 ± 5.9 | −1.1 ± 7.2 | 0.3 ± 2.1 | −0.3 ± 1.4 | −1.0 ± 1.4 | −0.4 ± 1.3 | − |
| BPP SSRI | 8.7 ± 12.6 | 7.5 ± 21.7 | 8.6 ± 9.5 | 4.7 ± 4.4 | 3.0 ± 4.0 | 5.2 ± 4.0 | − |
| Occupancy | −4.4 ± 8.8 | −4.3 ± 9.4 | −3.0 ± 2.4 | −2.3 ± 1.8 | −2.0 ± 1.9 | −2.4 ± 1.6 | − |
| AC pseudoCT | |||||||
| VT placebo | −0.4 ± 2.2 | 0.0 ± 1.8 | −0.1 ± 2.0 | 0.4 ± 2.3 | 0.5 ± 2.4 | −0.4 ± 1.9 | 0.0 ± 3.0 |
| VT SSRI | −0.6 ± 2.2 | 0.3 ± 1.5 | −0.3 ± 2.4 | 0.4 ± 1.8 | 0.5 ± 1.8 | −0.1 ± 1.7 | −0.3 ± 3.0 |
| BPP placebo | −2.0 ± 7.2 | 0.5 ± 8.2 | −0.3 ± 2.8 | 0.8 ± 3.5 | 0.8 ± 3.2 | −0.6 ± 2.4 | − |
| BPP SSRI | −3.7 ± 13.0 | 4.4 ± 22.3 | −0.2 ± 5.8 | 1.4 ± 4.2 | 1.7 ± 3.9 | 0.4 ± 3.9 | − |
| Occupancy | 1.0 ± 7.7 | −2.2 ± 8.9 | 0.0 ± 1.6 | −0.3 ± 2.2 | −0.4 ± 2.0 | −0.3 ± 1.7 | − |
| AC RESOLUTE | |||||||
| VT placebo | 4.5 ± 1.3 | 1.9 ± 0.9 | 5.3 ± 1.8 | 3.8 ± 1.3 | 3.8 ± 1.1 | 3.4 ± 1.0 | 2.5 ± 2.2 |
| VT SSRI | 4.4 ± 1.5 | 2.2 ± 0.7 | 5.2 ± 1.5 | 4.1 ± 1.1 | 4.5 ± 1.1 | 4.2 ± 1.1 | 2.3 ± 2.1 |
| BPP placebo | 10.4 ± 6.0 | 0.8 ± 7.0 | 8.0 ± 3.1 | 4.8 ± 2.3 | 4.7 ± 1.5 | 4.0 ± 1.4 | − |
| BPP SSRI | 16.6 ± 10.4 | 4.0 ± 20.3 | 13.4 ± 6.6 | 7.5 ± 3.2 | 8.0 ± 3.3 | 7.3 ± 3.3 | − |
| Occupancy | −4.2 ± 6.4 | −1.2 ± 8.1 | −2.2 ± 2.0 | −1.3 ± 2.1 | −1.7 ± 1.9 | −1.4 ± 1.5 | − |
| AC BD | |||||||
| VT placebo | −6.0 ± 1.6 | −4.6 ± 2.4 | −2.5 ± 1.4 | −3.9 ± 1.6 | −4.3 ± 1.6 | −4.7 ± 1.8 | −4.3 ± 2.8 |
| VT SSRI | −6.5 ± 1.6 | −4.1 ± 1.7 | −2.9 ± 1.7 | −3.6 ± 1.8 | −4.0 ± 1.7 | −4.4 ± 1.7 | −5.2 ± 3.2 |
| BPP placebo | −11.1 ± 5.0 | −5.7 ± 8.8 | −0.9 ± 3.2 | −3.6 ± 2.2 | −4.4 ± 2.0 | −4.9 ± 2.1 | − |
| BPP SSRI | −15.4 ± 10.5 | 1.2 ± 18.7 | 2.9 ± 6.5 | −1.0 ± 5.9 | −2.4 ± 4.4 | −3.2 ± 4.9 | − |
| Occupancy | 0.9 ± 16.9 | −8.3 ± 24.9 | −1.9 ± 2.0 | −1.5 ± 3.7 | −1.3 ± 3.3 | −0.8 ± 2.7 | − |